Danish allergy company ALK-Abelló has signed a strategic partnership with Chinese biopharmaceutical firm GenSci to develop and commercialise its house dust mite allergy immunotherapy (AIT) products in China. Under the agreement, GenSci gains exclusive rights to ALK’s products Alutard® and ACARIZAX® until the end of 2039. “We’re very excited about the prospects of speeding up market uptake of ALK’s evidence-based AIT products in China. China has the world’s largest population suffering from house dust mite allergy, yet fewer than one million people are currently treated with AIT. Through the new partnership, ALK and GenSci aim to expand market penetration by investing in awareness campaigns, hospital collaborations, and digital healthcare initiatives.